BofA raised the firm’s price target on Travere Therapeutics (TVTX) to $44 from $43 and keeps a Buy rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings “may not have the same impact they’ve had in prior years,” the analyst tells investors in a preview for the firm’s biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics put volume heavy and directionally bearish
- Travere Therapeutics price target lowered to $43 from $47 at BofA
- Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset
- Top 5 Trending Stocks by Unusual Trading Volume, 1/14/26
- FDA Extends Review Timeline for Travere’s FILSPARI sNDA